Good to note this , Fid ...thanks .
Whilst it might be a complete waste of time , interesting to read this on the Renova RX website :
RenovoRx CEO to Provide Strategic Update During Fireside Chat on Thursday, April 3rd at 12:00 p.m. ET :: RenovoRX, Inc. (RNXT)
What caught my eye --was this part :Way above my pay grade and understanding ...but perhaps the work that IMU is doing on Bile Duct Cancer ...and this delivery for pancreatic cancer , can draw IMU and Renova , to another complimentary association to two of the more "difficult "cancerous areas ??
treatment of locally advanced pancreatic cancer (LAPC).
Mr. Bagai will also discuss progress on RenovoRx’s ongoing Phase III TIGeR-PaC clinical trial. TIGeR-PaC is evaluating the Company’s lead drug-device combination product candidate (intra-arterial delivery of gemcitabine via the RenovoCath catheter), known as IAG which uses the proprietary Trans-Arterial Micro-Perfusion (TAMP™) therapy platform for the treatment of locally advanced pancreatic cancer (LAPC). The combination product candidate (IAG), which is enabled by the FDA-cleared RenovoCath device, is currently under investigation and has not been approved for commercial sale.
(20min delay)